What is Sutro Biopharma's G&A?

Sutro Biopharma (STRO) reported G&A of $7.58M in Q1 2026.

How has Sutro Biopharma's G&A changed year-over-year?

Sutro Biopharma's G&A decreased by 42.9% year-over-year, from $13.27M to $7.58M.

What is the long-term trend for Sutro Biopharma's G&A?

Over 4 years (2021 to 2025), Sutro Biopharma's G&A has grown at a -7.5% compound annual growth rate (CAGR), from $56M to $41.02M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Sutro Biopharma STRO G&A

G&A at other companies

RegenxbioRGNX

$21.31M+4.7%

Nuvectis Pharma, Inc.NVCT

$2.15M+14.1%

XencorXNCR

$17.71M+2.1%

AnaptysBio, Inc.ANAB

$26.2M+85.4%

SchrodingerSDGR

$22.91M-11.2%

CytomX TherapeuticsCTMX

$10.69M+13.4%

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's G&A?: Sutro Biopharma (STRO) reported G&A of $7.58M in Q1 2026.
How has Sutro Biopharma's G&A changed year-over-year?: Sutro Biopharma's G&A decreased by 42.9% year-over-year, from $13.27M to $7.58M.
What is the long-term trend for Sutro Biopharma's G&A?: Over 4 years (2021 to 2025), Sutro Biopharma's G&A has grown at a -7.5% compound annual growth rate (CAGR), from $56M to $41.02M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.